美国食品和药物管理局拒绝批准MDMA PTSD治疗, FDA denies MDMA PTSD treatment approval due to abuse and long-term concerns, sparking debate.

美国食品和药物管理局拒绝批准使用MDMA作为PTSD治疗, The FDA denied approval for MDMA as a PTSD treatment, sparking debate among patients, researchers, and advocates. 临床试验显示出有希望的结果,但对潜在滥用和长期影响的关切导致拒绝治疗。 Clinical trials showed promising results, but concerns over potential abuse and long-term effects led to refusal. 支持者认为,MDMA辅助疗法胜过风险,而批评者则强调更安全的替代品。 Supporters argue MDMA-assisted therapy outweighs risks, while critics stress on safer alternatives. 这一决定引发了人们对 FDA 审批程序和非常规治疗未来的质疑。 The decision raises questions about the FDA's approval process and the future of unconventional treatments.